Development of an implantable anticancer drug for prevention of local tumor recurrence and eradication of existing metastases after tumor resection of triple-negative breast cancer(TNBC)

INTEROLIGO Corporation



ONCOLOGY	Lead						
Product Type	Impla	Implantable Target Therapy					
Indication	Triple	Triple-negative Breast Cancer (TNBC)					
Target		Patients with Triple-negative Breast Cancer(TNBC) applied for tumor recurrence prevention and metastasis eradication after surgical operation					
MoA(Mechanism of Action)		Prevention of local tumor recurrence and eradication of existing metastases after tumor resection of Triple-negative Breast Cancer(TNBC)					
Competitiveness	exper	Most of the drugs known so far show that the survival rate after 70 days of the experimental animal is 60~70%. But our drug shows a 100% survival rate, and there has been no result showing such survival rate in animal experiments.					
		Institute	Interoligo	Dana-Faber Cancer Institute/Harvard Medical School	Wyss Institute/Harvard University (Novatis)	-	
		Drug Implantation	[Gem-aptamer]- loaded Collagen	[STING-RR]-loaded Hydrogel	[GM-CSF/CPG- oligonucleotide/Dox- iRGD Conjugate]- loaded Arginate Gel		
		Formulation		5 mm	Macroporous gel		
		Survival rate	100%	70%	60%	_	
		Survivar rate after 70 days after tumor resection and insertion	100 100 100 100 100 100 100 100	100 80 80 80 80 80 80 80 80 80 80 80 80 8	100 100 100 100 100 100 100 100 100 100		
		Recurrence and metastasis	Nor observed	Partly occured	Partly occured		
		Ref.	Not published	Sci. Transal. Med., 2018, 10, eaar1916	Nature Communications, 2020 , 11, 5696		



Development Stage

Route of Administration

Lead

Implantation